CA1222953A - Agent and process for optimizing the tissue mass of organs within the range of genetic variation in humans and animals - Google Patents
Agent and process for optimizing the tissue mass of organs within the range of genetic variation in humans and animalsInfo
- Publication number
- CA1222953A CA1222953A CA000439682A CA439682A CA1222953A CA 1222953 A CA1222953 A CA 1222953A CA 000439682 A CA000439682 A CA 000439682A CA 439682 A CA439682 A CA 439682A CA 1222953 A CA1222953 A CA 1222953A
- Authority
- CA
- Canada
- Prior art keywords
- agent
- nucleic acid
- acid base
- adenine
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract of the disclosure The following can be used as active compounds to optimize the tissue mass of organs within the range of genetic variation of humans and animals:
a) oligonucleotides, the terminal bases of which differ from adenine, and/or b) nucleic acid bases, with the exception of adenine, and/or c) carboxyl derivatives of nucleic acid bases, with the exception of adenine, and/or d) amino derivatives of nucleic acid bases, with the exception of adenine.
a) oligonucleotides, the terminal bases of which differ from adenine, and/or b) nucleic acid bases, with the exception of adenine, and/or c) carboxyl derivatives of nucleic acid bases, with the exception of adenine, and/or d) amino derivatives of nucleic acid bases, with the exception of adenine.
Description
29~3 Agent and process for optimizing the tissue mass of organs within the range of genetic variation in humans and animals.
It is known, from the Merck Index, 9th Edition, Rahway, N.Y., U.S.A., 1976, that orotic acid, that is to say a uracil-carboxylic acid of the formula:
H
0~0 ~N-H
COOH
has been proposed as a feed additive, combined with methionine, for promoting the growth of calves. The addition of a thiouracil-carboxylic acid, its non-toxic salt and/or its alkyl ester to the feed is proposed, in Swiss Patent Specification No.505,560, for im-proving the growth and other advantageous properties of usefulanimals. In addition, if desired, a biological methylating agent, such as methionine, and/or a uracilcarboxylic acid, its non-toxic salt and/or its alkyl ester can be added.
It has now been found that certain oligonucleotides, nucleic acid bases, and carboxyl derivatives and amino derivative of nucleic acid bases can be used to optimize the tissue mass of organs of humans and animals within their range of genetic varia-tion. It is well known that there is a variation in the extent of materialization, during protein biosynthesis, of the genetic information which is encoded in the DNA of humans and animals, and this results in a certain range of variation in respect of the development of the relevant organs. The abovementioned active com-
It is known, from the Merck Index, 9th Edition, Rahway, N.Y., U.S.A., 1976, that orotic acid, that is to say a uracil-carboxylic acid of the formula:
H
0~0 ~N-H
COOH
has been proposed as a feed additive, combined with methionine, for promoting the growth of calves. The addition of a thiouracil-carboxylic acid, its non-toxic salt and/or its alkyl ester to the feed is proposed, in Swiss Patent Specification No.505,560, for im-proving the growth and other advantageous properties of usefulanimals. In addition, if desired, a biological methylating agent, such as methionine, and/or a uracilcarboxylic acid, its non-toxic salt and/or its alkyl ester can be added.
It has now been found that certain oligonucleotides, nucleic acid bases, and carboxyl derivatives and amino derivative of nucleic acid bases can be used to optimize the tissue mass of organs of humans and animals within their range of genetic varia-tion. It is well known that there is a variation in the extent of materialization, during protein biosynthesis, of the genetic information which is encoded in the DNA of humans and animals, and this results in a certain range of variation in respect of the development of the relevant organs. The abovementioned active com-
- 2 - ~222953 pounds now make it possible to materialize genetic information to an optimal extent.
It has also emerged that adenine, as well as its carboxyl derivatives and amino derivatives, and oligonucleotides which contain adenine as the terminal bases, cannot be used for the invention. Thus the invention relates to an agent for optimiz-ing the tissue mass of organs within the range of genetic varia-tion of humans and animals, which agent contains and/or at least one oligonucleotide, the terminal bases of which differ from adenine, and/or at least one nucleic acid base, with the exception of adenine, and/or at least one carboxyl derivative of a nucleic acid base, with the exception of adenine, and/or at least one amino derivative of a nucleic acid base, with the exception of adenine, as the active compound(s), combined with a vehicle.
Furthermore, the invention relates to a process for optimizing the tissue mass of organs within the range of genetic variation of humans and animals, which comprises introducing and/or at least one oligonucleotide, the terminal bases of which differ from adenine, and/or at least one nucleic acid base, with the exception of adenine, and/or at least one carboxyl derivative of a nucleic acid base, with the exception of adenine and/or at least one amino derivative of a nucleic acid base, with the exception of adenine, as the active compound(s) into the human or animal body.
"Oligonucleotides" are well known to include linear sequences of a maximum of 20 units which, depending on the chain length, are denoted di-, tri-, tetra-, penta-nucleotides etc. The terminal sugars are phosphorylated in these ologonucleotides.
~, , 29S~
It has also emerged that adenine, as well as its carboxyl derivatives and amino derivatives, and oligonucleotides which contain adenine as the terminal bases, cannot be used for the invention. Thus the invention relates to an agent for optimiz-ing the tissue mass of organs within the range of genetic varia-tion of humans and animals, which agent contains and/or at least one oligonucleotide, the terminal bases of which differ from adenine, and/or at least one nucleic acid base, with the exception of adenine, and/or at least one carboxyl derivative of a nucleic acid base, with the exception of adenine, and/or at least one amino derivative of a nucleic acid base, with the exception of adenine, as the active compound(s), combined with a vehicle.
Furthermore, the invention relates to a process for optimizing the tissue mass of organs within the range of genetic variation of humans and animals, which comprises introducing and/or at least one oligonucleotide, the terminal bases of which differ from adenine, and/or at least one nucleic acid base, with the exception of adenine, and/or at least one carboxyl derivative of a nucleic acid base, with the exception of adenine and/or at least one amino derivative of a nucleic acid base, with the exception of adenine, as the active compound(s) into the human or animal body.
"Oligonucleotides" are well known to include linear sequences of a maximum of 20 units which, depending on the chain length, are denoted di-, tri-, tetra-, penta-nucleotides etc. The terminal sugars are phosphorylated in these ologonucleotides.
~, , 29S~
- 3 The action of the abovementioned active compounds can be explained by their penetration into the cells and their inhibition there of the lytic enzymes, particularly the deaminases. Thus, these enzymes are unable, or in any event are less able, to decom-pose aminoacids which derive from digested proteins. As a result, more aminoacids are available for constructive metabolism, which leads to more rapid multiplication and improved differentiation of the affected cells.
Pancreatic ribonucleases, which degrade ribonucleic acid to nucleotides, are present in the digestive tract of humans and animals. Thus, it could be assumed that, by administration of ribonucleic acid from yeast or other sources, the same effects could be achieved as with the active compounds used according to the invention, since the ribonucleic acids are certainly also de-graded to nucleotides. However, surprisingly, it has emerged that this is not the case.
In principle, the abovementioned active compounds affect assemblages of cells which are undergoing extensive division or rapid growth. When the active compounds are administered to the mother animals before delivery and/or to the young immediately after delivery, they bring about an intensive development of the endocrine glands and of the lymphatic system in the embryonal state or shortly after delivery. The active compounds also pro-mote the growth of voluntary muscles. However, depending on the composition of the active compounds, the effect extends preferenti-ally to a variety of organs. For example, nucleic acid bases and di- to tetranucleotides particularly affect embryonal tissue, while octa- ~o tetradecanucleoti~es particll1arly act on voluntary muscles. The expert is able to determine straightforwardly by experiment the tissue on which particular active compounds exert an especially potent effect.
When the development of particular organs has been pro-moted in the embryonal state by the above active compounds, then the following effects emerge:
Improved development of the pituitary leads to greater production of somatotrophic hormone, the natural growth hormone.
Improved development of the sex organs brings about better results of breeding.
Improved development of pancreatic tissue causes in-creased secretion of insulin which favors more rapid growth.
Improved development of lymphatic system and thymus pro-vide increased resistance against diseases.
It has been found, for example, that, on administration of a mixture of nucleic acid bases with di-, tri- and, possibly, tetranucleotides to BALB/c mice or Swiss mice, there is a statistically significant increase in the spleen cells which pro-duce antibodies.
On investigation of the susceptibility of complement-dependent immunohemolysis in vitro to effects by the same active compounds, using human complement, potent activation of complement emerged even at a low concentration.
The active compounds used according to the invention are known and can be prepared in a manner known per se.
The agents or active compounds according to the inven-12~953 tion can be administered by in~usion or injection or per os.
Depending on the mode of administration, suitable vehicles for the active compounds according to the invention are the known vehicles which are acceptable for pharmaceutical or veterinary use, or, for animals, also the feed or the drinking water. Examples of suit-able vehicles are lactose, potato starch and corn starch, talc, gelatin, stearic acid, silica, sterile fluids, such as pyrogen-free water, or oils, for example peanut oil.
The agents according to the invention can be in the form of concentrates or dose units, such as capsules, uncoated or coated tablets, etc. In this case, as a rule, they contain 1 to 200 mg, preferably 30 to 150 mg, in particular about 80 mg, of active compound(s) per g. On the other hand, when they are in the form of feedstuff ready for use or drinking water, they normally contain 1 to 200 mg, preferably 30 to 150 mg, in particular about 80 mg, of active compound(s) per kg. Usually, the active com-pounds are administered in amounts of 0.02 to 10 mg, preferably 2 to 6 mg, in particular about 3 mg, per kg of body weight and day.
Preparation of the active compounds .
The nucleic bases and oligonucleotides were prepared and separated by the methods given in Die Hefen (The Yeasts), Volume I:
Die Hefen in der Wissenschaft (Yeasts in Science), published by Hans Carl, Nurnberg 1960 (pages 415 ff, 435 ff and 439, and list of references on pages 440 to 445). A low molecular weight frac-tion (LF) and a high molecular weight fraction (HF) from the enzymatic cleavage of yeast RNA were used in the examples. The ratios of amounts of the individual units were unchanged and were the same as those in the RNA used as starting materiaL. The LF
comprised nucleic acid bases, and mono-, di-, tri- and tetra-nucleotides. The HF contained the higher oligonucleotides, octa-to tetra- octa- to tetradecanucleotides.
Example 1 A homogeneous mixture was produced of 80 g of HF dry sub-stance with 25 g each of the nucleic acid bases uracil and guanine together with 870 g of whey powder. 500 g of this mixture were incorporated into 1,000 kg of a complete feed for fattening pig-lets. Piglets of 25 kg live weight were fed with this feed mix-ture up to a finishing weight of 100 kg.
The longissimus dorsi muscle (the loin) of the .
.
:
':
122~953 p;glets which had been fed with the feed containing the agent according to the invent;on ~as much more greatly developed than in piglets which had been fed with the same feed without the add;tion of the agent according to the S invention up to the same finishing weight. The method ~hich is customary among special;sts for detect;ng this effect comprises measuring the so-called area of the Loin, that is to say the cross-sectional area of the longissimus dorsi muscle. In the present example, a statistically significant increase in the area of the loin from 31.8 cm2 to 35.5 cm2 was achieved.
Example 2 A homogeneous m;xture was produced from 100 9 of `
LF dry substance with 45 9 of the nucleic acid base uracil and 40 9 of uracilcarboxylic acid together with 815 9 of "distillers' dried solubles" as the vehicle.
500 9 of this concentrate were mixed into 1,ûO0 kg of a complete feed for breeding pigs which was nutritiona~ly adequate in every aspect. Pregnant breeding sows were fed with this until they littered.
The total glandular mass of the piglets, comprising the thymus, lymph nodes, pituitary, adrenals, pancreas and liver, was increased by 15 to 25Z, that is to say to the upper limit of the range of genetic variation. It is also possible to use aminouracil in place of uracilcar-boxylic acid.
Example 3 100 9 of LF, 38 9 of the nucleic acid base thymine, 22 9 of the nucleic acid base guanine and 15 9 of the 12Z~9$3 nucleic acid base uracil were permanently suspended in water w;th the addition of protect;ve co~Loids and emulsi-fiers, preservatives were added and the voLume was made up to 1 l;ter. 100 ml of th;s concentrated suspension was 5 stirred into 100 liters of drinking water for geese.
The birds which were treated w;th th;s drinking water dur;ng rear;ng unt;l they reached adult ~eight developed the genetically optimal mass of liver substance (on average more than 20X more liver tissue of the highest 10 biologic quality).
Example 4 Enteric gelatin capsules were each filled ~ith 150 mg of HF dry substance. Adult humans who ~ere taking pa-rt in "body-building" training received admi`nistrations 15 of one capsule three times a day. With otherwise identi-cal nutrition, movement and exercise, the tissue mass tvolume) of all the strong voluntary muscles was ;ncreased, and this was clearly visible and easily measurable. This was also evident from an increase in performance which could be objectively measured.
:
~ , .
. ~
Pancreatic ribonucleases, which degrade ribonucleic acid to nucleotides, are present in the digestive tract of humans and animals. Thus, it could be assumed that, by administration of ribonucleic acid from yeast or other sources, the same effects could be achieved as with the active compounds used according to the invention, since the ribonucleic acids are certainly also de-graded to nucleotides. However, surprisingly, it has emerged that this is not the case.
In principle, the abovementioned active compounds affect assemblages of cells which are undergoing extensive division or rapid growth. When the active compounds are administered to the mother animals before delivery and/or to the young immediately after delivery, they bring about an intensive development of the endocrine glands and of the lymphatic system in the embryonal state or shortly after delivery. The active compounds also pro-mote the growth of voluntary muscles. However, depending on the composition of the active compounds, the effect extends preferenti-ally to a variety of organs. For example, nucleic acid bases and di- to tetranucleotides particularly affect embryonal tissue, while octa- ~o tetradecanucleoti~es particll1arly act on voluntary muscles. The expert is able to determine straightforwardly by experiment the tissue on which particular active compounds exert an especially potent effect.
When the development of particular organs has been pro-moted in the embryonal state by the above active compounds, then the following effects emerge:
Improved development of the pituitary leads to greater production of somatotrophic hormone, the natural growth hormone.
Improved development of the sex organs brings about better results of breeding.
Improved development of pancreatic tissue causes in-creased secretion of insulin which favors more rapid growth.
Improved development of lymphatic system and thymus pro-vide increased resistance against diseases.
It has been found, for example, that, on administration of a mixture of nucleic acid bases with di-, tri- and, possibly, tetranucleotides to BALB/c mice or Swiss mice, there is a statistically significant increase in the spleen cells which pro-duce antibodies.
On investigation of the susceptibility of complement-dependent immunohemolysis in vitro to effects by the same active compounds, using human complement, potent activation of complement emerged even at a low concentration.
The active compounds used according to the invention are known and can be prepared in a manner known per se.
The agents or active compounds according to the inven-12~953 tion can be administered by in~usion or injection or per os.
Depending on the mode of administration, suitable vehicles for the active compounds according to the invention are the known vehicles which are acceptable for pharmaceutical or veterinary use, or, for animals, also the feed or the drinking water. Examples of suit-able vehicles are lactose, potato starch and corn starch, talc, gelatin, stearic acid, silica, sterile fluids, such as pyrogen-free water, or oils, for example peanut oil.
The agents according to the invention can be in the form of concentrates or dose units, such as capsules, uncoated or coated tablets, etc. In this case, as a rule, they contain 1 to 200 mg, preferably 30 to 150 mg, in particular about 80 mg, of active compound(s) per g. On the other hand, when they are in the form of feedstuff ready for use or drinking water, they normally contain 1 to 200 mg, preferably 30 to 150 mg, in particular about 80 mg, of active compound(s) per kg. Usually, the active com-pounds are administered in amounts of 0.02 to 10 mg, preferably 2 to 6 mg, in particular about 3 mg, per kg of body weight and day.
Preparation of the active compounds .
The nucleic bases and oligonucleotides were prepared and separated by the methods given in Die Hefen (The Yeasts), Volume I:
Die Hefen in der Wissenschaft (Yeasts in Science), published by Hans Carl, Nurnberg 1960 (pages 415 ff, 435 ff and 439, and list of references on pages 440 to 445). A low molecular weight frac-tion (LF) and a high molecular weight fraction (HF) from the enzymatic cleavage of yeast RNA were used in the examples. The ratios of amounts of the individual units were unchanged and were the same as those in the RNA used as starting materiaL. The LF
comprised nucleic acid bases, and mono-, di-, tri- and tetra-nucleotides. The HF contained the higher oligonucleotides, octa-to tetra- octa- to tetradecanucleotides.
Example 1 A homogeneous mixture was produced of 80 g of HF dry sub-stance with 25 g each of the nucleic acid bases uracil and guanine together with 870 g of whey powder. 500 g of this mixture were incorporated into 1,000 kg of a complete feed for fattening pig-lets. Piglets of 25 kg live weight were fed with this feed mix-ture up to a finishing weight of 100 kg.
The longissimus dorsi muscle (the loin) of the .
.
:
':
122~953 p;glets which had been fed with the feed containing the agent according to the invent;on ~as much more greatly developed than in piglets which had been fed with the same feed without the add;tion of the agent according to the S invention up to the same finishing weight. The method ~hich is customary among special;sts for detect;ng this effect comprises measuring the so-called area of the Loin, that is to say the cross-sectional area of the longissimus dorsi muscle. In the present example, a statistically significant increase in the area of the loin from 31.8 cm2 to 35.5 cm2 was achieved.
Example 2 A homogeneous m;xture was produced from 100 9 of `
LF dry substance with 45 9 of the nucleic acid base uracil and 40 9 of uracilcarboxylic acid together with 815 9 of "distillers' dried solubles" as the vehicle.
500 9 of this concentrate were mixed into 1,ûO0 kg of a complete feed for breeding pigs which was nutritiona~ly adequate in every aspect. Pregnant breeding sows were fed with this until they littered.
The total glandular mass of the piglets, comprising the thymus, lymph nodes, pituitary, adrenals, pancreas and liver, was increased by 15 to 25Z, that is to say to the upper limit of the range of genetic variation. It is also possible to use aminouracil in place of uracilcar-boxylic acid.
Example 3 100 9 of LF, 38 9 of the nucleic acid base thymine, 22 9 of the nucleic acid base guanine and 15 9 of the 12Z~9$3 nucleic acid base uracil were permanently suspended in water w;th the addition of protect;ve co~Loids and emulsi-fiers, preservatives were added and the voLume was made up to 1 l;ter. 100 ml of th;s concentrated suspension was 5 stirred into 100 liters of drinking water for geese.
The birds which were treated w;th th;s drinking water dur;ng rear;ng unt;l they reached adult ~eight developed the genetically optimal mass of liver substance (on average more than 20X more liver tissue of the highest 10 biologic quality).
Example 4 Enteric gelatin capsules were each filled ~ith 150 mg of HF dry substance. Adult humans who ~ere taking pa-rt in "body-building" training received admi`nistrations 15 of one capsule three times a day. With otherwise identi-cal nutrition, movement and exercise, the tissue mass tvolume) of all the strong voluntary muscles was ;ncreased, and this was clearly visible and easily measurable. This was also evident from an increase in performance which could be objectively measured.
:
~ , .
. ~
Claims (11)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An agent for optimizing the tissue mass of organs within the range of genetic variation of humans and animals, which con-tains at least one oligonucleotide, the terminal bases of which differ from adenine, and/or at least one nucleic acid base, with the exception of adenine, and/or at least one carboxyl derivative of a nucleic acid base, with the exception of adenine, and/or at least one amino derivative of a nucleic acid base, with the excep-tion of adenine, as active compound(s) combined with a vehicle.
2. The agent as claimed in claim 1 in the form of a concen-trate or a dose unit, which contains 1 to 200 mg, active com-pound(s) per g.
3. The agent as claimed in claim 2 which contains 30 to 150 mg active compound(s) per g.
4. The agent as claimed in claim 3 which contains about 80 mg active compound(s) per g.
5. The agent as claimed in claim 1 in the form of a feed-stuff ready for use or drinking water, which contains 1 to 200 mg, of active compound(s) per kg.
6. The agent as claimed in claim 5 which contains 30 to 150 mg of active compounds per kg.
7. The agent as claimed in claim 6 which contains about 80 mg of active compounds per kg.
8. The agent as claimed in claim 1, which contains, as active compound(s), at least one di-, tri- or tetranucleotide.
9. The active agent as claimed in claim 8 further contain-ing at least one nucleic acid base and/or at least one carboxyl derivative of a nucleic acid base and/or at least one amino deriva-tive of a nucleic acid base.
10. The agent as claimed in claim 1, which contains, as active compound(s), at least one octa- to tetradecanucleotide to-gether.
11. The active agent as claimed in claim 10 further contain-ing at least one nucleic acid base and/or at least one carboxyl derivative of a nucleic acid base and/or at least one amino deriva-tive of a nucleic acid base.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH624382 | 1982-10-26 | ||
| CH6243/82 | 1982-10-26 | ||
| CH6652/82A CH650906A5 (en) | 1982-11-15 | 1982-11-15 | Composition for optimising the tissue biomass of organs within the genetic range of variation in humans and animals |
| CH6652/82 | 1982-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1222953A true CA1222953A (en) | 1987-06-16 |
Family
ID=25699243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000439682A Expired CA1222953A (en) | 1982-10-26 | 1983-10-25 | Agent and process for optimizing the tissue mass of organs within the range of genetic variation in humans and animals |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0107161B1 (en) |
| CA (1) | CA1222953A (en) |
| DE (1) | DE3380342D1 (en) |
| DK (1) | DK484883A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0196530A3 (en) * | 1985-03-26 | 1989-03-22 | CTA Finanz AG | Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals |
| ES2007350A6 (en) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
| GB2216416B (en) * | 1988-03-11 | 1992-06-24 | Sandoz Ltd | Nucleobase source for the stimulation of the immune system |
| EP0422011A1 (en) * | 1988-05-05 | 1991-04-17 | BASF Aktiengesellschaft | Substances based on uracil-derivates for stimulating growth and reducing fat in animals |
| DE4102240C1 (en) * | 1991-01-24 | 1992-04-09 | Birkmayer, Joerg, Univ.-Prof. Ddr., Wien, At | |
| EP1455593B1 (en) | 2001-10-06 | 2013-07-24 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2328355A (en) * | 1941-06-20 | 1943-08-31 | Lederle Lab Inc | Animal growth promoting substance |
| DE1212826B (en) * | 1960-02-24 | 1966-03-17 | Bierhefe Verarbeitungsgesellsc | Feed additive and process for its manufacture |
| FR1392643A (en) * | 1963-02-05 | 1965-03-19 | Chemoforma Ag | Nutrient composition for poultry |
| DE1470190A1 (en) * | 1963-05-07 | 1969-04-10 | Rystan Company Mount Vernon | Process for the preparation of a therapeutic |
| GB1046770A (en) * | 1963-05-14 | 1966-10-26 | James Harrison Stanton | Therapeutic composition containing mycelial matter |
| GB1132322A (en) * | 1965-10-18 | 1968-10-30 | Yamasa Shoyu Kk | Nutrient-fortified foods and animal feeds and methods of producing and using the same |
| GB1200583A (en) * | 1968-03-22 | 1970-07-29 | Ralston Purina Co | Hydrolysis of ribonucleic acid-containing materials |
| IT1043823B (en) * | 1970-11-03 | 1980-02-29 | Prephar | PROCEDURE FOR THE EXTRACTION OF NUCLEIC ACIDS FROM ANIMAL BODIES |
-
1983
- 1983-10-17 DE DE8383110325T patent/DE3380342D1/en not_active Expired
- 1983-10-17 EP EP83110325A patent/EP0107161B1/en not_active Expired
- 1983-10-21 DK DK484883A patent/DK484883A/en not_active Application Discontinuation
- 1983-10-25 CA CA000439682A patent/CA1222953A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DK484883D0 (en) | 1983-10-21 |
| DK484883A (en) | 1984-04-27 |
| EP0107161A3 (en) | 1984-06-06 |
| EP0107161A2 (en) | 1984-05-02 |
| EP0107161B1 (en) | 1989-08-09 |
| DE3380342D1 (en) | 1989-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McAllan | The degradation of nucleic acids in, and the removal of breakdown products from the small intestines of steers | |
| EP2218337B1 (en) | Mimicking the metabolic effects of caloric restriction by administration of glucose anti-metabolites | |
| US20090252834A1 (en) | Compositions comprising glucose anti-metabolites | |
| Campbell et al. | Effects of gender and genotype on the response of growing pigs to exogenous administration of porcine growth hormone | |
| Lobley et al. | Protein synthesis in splanchnic tissues of sheep offered two levels of intake | |
| Gill et al. | High, medium and low corn silage diets with and without monensin for feedlot steers | |
| Larsen et al. | Effect of selenium on sheep lymphocyte responses to mitogens | |
| Chiba | Effects of nutritional history on the subsequent and overall growth performance and carcass traits of pigs | |
| CA1222953A (en) | Agent and process for optimizing the tissue mass of organs within the range of genetic variation in humans and animals | |
| JP2002529108A (en) | Method for supplying bioavailable methionine to cows | |
| Hemre et al. | 14C‐glucose injection in Atlantic cod, Gadus morhua, metabolic responses and excretion via the gill membrane | |
| Maage et al. | Ascorbate-2-sulfate as a dietary vitamin C source for Atlantic salmon (Salmo salar): 2. Effects of dietary levels and immunization on the metabolism of trace elements | |
| Nation et al. | Clinical signs and pathology of accidental monensin poisoning in sheep | |
| Brown et al. | Lysine requirement of the finishing pig for maximum rate of gain and efficiency | |
| Phillips et al. | Characteristics of threonine, valine and methionine absorption in the jejunum and ileum of sheep | |
| NAGAMINE et al. | Effects of the castration on the growth, meat production and odors in male goats | |
| EP0196530A2 (en) | Agent and process for increasing growth, for optimizing fertility and for stimulating the immune system in humans and animals | |
| Braude et al. | Observations on the nicotinic acid requirements of pigs | |
| Lone et al. | Cellular effects of adrenosterone feeding to juvenile carp, Cyprinus carpio L., effect on liver, kidney, brain and muscle protein and nucleic acids | |
| Katzeff et al. | Effects of exercise on protein synthesis and myosin heavy chain gene expression in hypothyroid rats | |
| CH650906A5 (en) | Composition for optimising the tissue biomass of organs within the genetic range of variation in humans and animals | |
| Haldar et al. | Effects of growth hormone-releasing factor on growth hormone response, growth and feed conversion efficiency in buffalo heifers (Bubalus bubalis) | |
| JPS59130221A (en) | Improver and improvement for organ tissue in human and animal immunological movement zone | |
| RU2189762C2 (en) | Biostimulating feeding additive | |
| Thomas et al. | Dietary factors affecting the utilisation of protein by laying hens and their effects on the concentrations of certain nitrogenous constituents in the excreta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |